Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Positive biomarker results presented from phase I study of XCUR-17

Oct. 17, 2019

Dermira initiates phase III program of lebrikizumab in atopic dermatitis

Oct. 10, 2019

Scenesse wins approval in U.S. for erythropoietic protoporphyria

Oct. 9, 2019

Dermavant initiates phase IIa study of cerdulatinib gel in vitiligo

Oct. 8, 2019

NKTR-358 begins new phase Ib studies in psoriasis and atopic dermatitis

Oct. 8, 2019

FDA approves Aklief cream for topical treatment of acne

Oct. 7, 2019

Shire Human Genetic Therapies presents new kallikrein B inhibitors

Oct. 7, 2019

Cabaletta Bio receives FDA IND clearance to initiate first-in-human study of DSG3-CAART

Oct. 2, 2019

AnaptysBio reports phase II interim data on ANB-019 in generalized pustular psoriasis

Oct. 1, 2019

Pfizer announces topline results from pivotal JADE MONO-2 study of abrocitinib

Sep. 30, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...